Akèy › Kansè fwa (Kasinòm epatoselilè) › Massachusetts › Boston
Etid klinik pou Kansè fwa (Kasinòm epatoselilè) nan Boston, MA
18 etid pou Kansè fwa (Kasinòm epatoselilè) ap chèche patisipan nan sit nan ak bò kote Boston (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Ap rekriteFaz 1
- Exelixis Clinical Site #7, Boston
National Liver Cancer Screening Trial
Ap rekriteFaz 4
- Massachusetts General Hospital, Boston
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
Ap rekriteFaz 1
- Mass General Cancer Center, Boston
Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
Ap rekriteFaz 2
- Massachusetts General Hospital, Boston
Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
Ap rekriteEtid obsèvasyon
- Mass General Brigham, Boston
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Ap rekriteFaz 1/2
- Dana-Farber Cancer Institute, Boston
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
Ap rekriteFaz 3
- Massachusetts General Hospital Cancer Center, Boston
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
Ap rekriteFaz 1/2
- Research Site, Boston
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Ap rekriteFaz 2
- Tufts Medical Center, Boston
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
Ap rekriteFaz 1/2
- Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
Ap rekrite
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
Ap rekriteFaz 1
- Mass General Brigham Cancer Institute, Boston
- Dana Farber Cancer Institute, Boston
Computer Guided Microwave Liver Ablation
Ap rekrite
- Massachusetts General Hospital, Boston
Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma
Ap rekriteFaz 2
- Children's Hospital Boston, Boston
- Dana Farber Cancer Institute, Boston
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
Ap rekriteFaz 4
- Massachussets General Hospital, Boston
Value of [68Ga]Ga-PSMA-11 PET/MRI in the Assessment of Liver Cirrhosis
Ap rekriteEtid obsèvasyon
- Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown · 1 mi lwen
Psychoeducational Intervention for Patients With Hepatocellular Carcinoma
Ap rekrite
- Massachusetts General Hospital, Boston
Etid Kansè fwa (Kasinòm epatoselilè) nan lòt vil
- Houston, TX31 etid
- New York City, NY24 etid
- Dallas, TX19 etid
- Los Angeles, CA19 etid
- Cleveland, OH18 etid
- Chicago, IL16 etid
- Philadelphia, PA16 etid
- Pittsburgh, PA15 etid
- San Francisco, CA14 etid
- Orange, CA14 etid
- Jacksonville, FL14 etid
- San Antonio, TX13 etid
Lòt etid nan Boston
- Kansè nan tete113 etid
- Kansè Poumon ki pa ti selil90 etid
- Kansè (tout kalite)84 etid
- Kansè kolorektal64 etid
- Kansè Metastatik63 etid
- Kansè poumon62 etid
- Kansè ovè61 etid
- Kansè pwostat59 etid
- Depresyon52 etid
- Kansè Endomèt50 etid
- Ensifizyans kadyak44 etid
- Leksemi mieloïd egi44 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 7, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.